{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T16:58:55Z","timestamp":1771001935468,"version":"3.50.1"},"reference-count":106,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1016\/j.urolonc.2013.07.011","type":"journal-article","created":{"date-parts":[[2013,11,13]],"date-time":"2013-11-13T12:15:57Z","timestamp":1384344957000},"page":"243-251","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Biomarkers of renal cell carcinoma"],"prefix":"10.1016","volume":"32","author":[{"given":"Tin C.","family":"Ngo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher G.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose A.","family":"Karam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2013.07.011_bib1","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.hoc.2011.04.002","article-title":"Epidemiology of renal cell cancer","volume":"25","author":"Cho","year":"2011","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.urolonc.2013.07.011_bib2","first-page":"11","article-title":"Cancer statistics, 2013","volume":"63","author":"Siegel","year":"2013","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urolonc.2013.07.011_bib3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.semcancer.2012.06.006","article-title":"An overview of renal cell cancer: pathology and genetics","volume":"23","author":"Moch","year":"2013","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.urolonc.2013.07.011_bib4","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0344-0338(86)80001-2","article-title":"Histopathology and classification of renal cell tumors (adenomas, oncocytomas and carcinomas). The basic cytological and histopathological elements and their use for diagnostics","volume":"181","author":"Thoenes","year":"1986","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.urolonc.2013.07.011_bib5","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/BF02890022","article-title":"The human chromophobe cell renal carcinoma: it\u2019s probable relation to intercalated cells of the collecting duct","volume":"56","author":"St\u00f6rkel","year":"1989","journal-title":"Virchows Arch B Cell Pathol Incl Mol Pathol"},{"key":"10.1016\/j.urolonc.2013.07.011_bib6","first-page":"461","article-title":"Characterisation of a collecting duct carcinoma by cytogenetic analysis and comparative genomic hybridisation","volume":"13","author":"Verdorfer","year":"1998","journal-title":"Int J Oncol"},{"key":"10.1016\/j.urolonc.2013.07.011_bib7","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.ucl.2008.07.005","article-title":"Epidemiology, clinical staging, and presentation of renal cell carcinoma","volume":"35","author":"Decastro","year":"2008","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.urolonc.2013.07.011_bib8","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nrc1364","article-title":"Searching for the hereditary causes of renal-cell carcinoma","volume":"4","author":"Pavlovich","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.urolonc.2013.07.011_bib9","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.eururo.2010.08.031","article-title":"Hereditary renal cancer syndromes: an update of a systematic review","volume":"58","author":"Verine","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2013.07.011_bib10","doi-asserted-by":"crossref","unstructured":"Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89\u201395","DOI":"10.1067\/mcp.2001.113989"},{"key":"10.1016\/j.urolonc.2013.07.011_bib11","first-page":"159","article-title":"Purification of a human prostate specific antigen","volume":"17","author":"Wang","year":"1979","journal-title":"Invest Urol"},{"key":"10.1016\/j.urolonc.2013.07.011_bib12","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1056\/NEJM198710083171501","article-title":"Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate","volume":"317","author":"Stamey","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2013.07.011_bib13","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0090-4295(75)90006-0","article-title":"Carcinoembryonic antigen test in renal cell carcinoma","volume":"5","author":"Guinan","year":"1975","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2013.07.011_bib14","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3233\/CBM-2011-0176","article-title":"Renal cell carcinoma","volume":"9","author":"Cairns","year":"2010","journal-title":"Cancer Biomark"},{"key":"10.1016\/j.urolonc.2013.07.011_bib15","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0094-0143(03)00023-5","article-title":"The genetic basis of renal cell carcinoma","volume":"30","author":"Pavlovich","year":"2003","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.urolonc.2013.07.011_bib16","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s13277-011-0257-3","article-title":"Role of VHL gene mutation in human renal cell carcinoma","volume":"33","author":"Arjumand","year":"2012","journal-title":"Tumour Biol"},{"key":"10.1016\/j.urolonc.2013.07.011_bib17","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.eururo.2009.01.003","article-title":"Diagnostic and prognostic molecular markers for renal cell carcinoma: a critical appraisal of the current state of research and clinical applicability","volume":"55","author":"Eichelberg","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2013.07.011_bib18","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nrurol.2010.47","article-title":"The genetic basis of kidney cancer: a metabolic disease","volume":"7","author":"Linehan","year":"2010","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.urolonc.2013.07.011_bib19","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1113205","article-title":"Intratumor heterogeneity and branched evolution revealed by multiregion sequencing","volume":"366","author":"Gerlinger","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2013.07.011_bib20","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/jjco\/hys200","article-title":"Proteomic approaches to the discovery of cancer biomarkers for early detection and personalized medicine","volume":"43","author":"Honda","year":"2013","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.urolonc.2013.07.011_bib21","doi-asserted-by":"crossref","first-page":"384","DOI":"10.2188\/jea.JE20120003","article-title":"DNA methylation in peripheral blood: a potential biomarker for cancer molecular epidemiology","volume":"22","author":"Li","year":"2012","journal-title":"J Epidemiol"},{"key":"10.1016\/j.urolonc.2013.07.011_bib22","doi-asserted-by":"crossref","first-page":"e19873","DOI":"10.1371\/journal.pone.0019873","article-title":"Vascular endothelial growth factor in the circulation in cancer patients may not be a relevant biomarker","volume":"6","author":"Niers","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.urolonc.2013.07.011_bib23","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.urolonc.2011.05.013","article-title":"Urine metabolomics for kidney cancer detection and biomarker discovery","volume":"29","author":"Ganti","year":"2011","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2013.07.011_bib24","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/00365590410002500","article-title":"Urinary nuclear matrix protein 22 for diagnosis of renal cell carcinoma","volume":"39","author":"Kaya","year":"2005","journal-title":"Scand J Urol Nephrol"},{"key":"10.1016\/j.urolonc.2013.07.011_bib25","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1097\/01.ju.0000095475.12515.5e","article-title":"Solid renal tumors: an analysis of pathological features related to tumor size","volume":"170","author":"Frank","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2013.07.011_bib26","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1089\/end.2011.0599","article-title":"Evaluation of perirenal fat as a predictor of cT 1a renal cortical neoplasm histopathology and surgical outcomes","volume":"26","author":"Okhunov","year":"2012","journal-title":"J Endourol"},{"key":"10.1016\/j.urolonc.2013.07.011_bib27","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3233\/CH-2010-1352","article-title":"The value of contrast enhanced ultrasound (CEUS) in the characterisation of patients with renal masses","volume":"46","author":"Ignee","year":"2010","journal-title":"Clin Hemorheol Microcirc"},{"key":"10.1016\/j.urolonc.2013.07.011_bib28","first-page":"7075","article-title":"Hypoxia-inducible expression of tumor-associated carbonic anhydrases","volume":"60","author":"Wykoff","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2013.07.011_bib29","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1097\/01.ju.0000116444.08690.e2","article-title":"Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma","volume":"171","author":"Bui","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2013.07.011_bib30","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.eururo.2012.08.024","article-title":"Phase 1 radioimmunotherapy study with lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma","volume":"64","author":"Stillebroer","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2013.07.011_bib31","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/nrurol.2010.40","article-title":"Functional imaging of renal cell carcinoma","volume":"7","author":"Lawrentschuk","year":"2010","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.urolonc.2013.07.011_bib32","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1200\/JCO.2011.41.2445","article-title":"Positron emission tomography\/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial","volume":"31","author":"Divgi","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2013.07.011_bib33","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1158\/0008-5472.CAN-12-3731","article-title":"Genome-wide epigenetic regulation of miRNAs in cancer","volume":"73","author":"Baer","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2013.07.011_bib34","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.yexmp.2012.10.005","article-title":"Serum miR-210 as a novel biomarker for molecular diagnosis of clear cell renal cell carcinoma","volume":"94","author":"Zhao","year":"2013","journal-title":"Exp Mol Pathol"},{"key":"10.1016\/j.urolonc.2013.07.011_bib35","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1479-5876-10-55","article-title":"Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma","volume":"10","author":"Redova","year":"2012","journal-title":"J Transl Med"},{"key":"10.1016\/j.urolonc.2013.07.011_bib36","doi-asserted-by":"crossref","first-page":"e25787","DOI":"10.1371\/journal.pone.0025787","article-title":"MicroRNAs in renal cell carcinoma: diagnostic implications of serum miR-1233 levels","volume":"6","author":"Wulfken","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.urolonc.2013.07.011_bib37","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/cncr.26254","article-title":"Serum cell-free DNA in renal cell carcinoma: a diagnostic and prognostic marker","volume":"118","author":"De Martino","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2013.07.011_bib38","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/j.juro.2011.05.085","article-title":"Serum amino acid levels as a biomarker for renal cell carcinoma","volume":"186","author":"Mustafa","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2013.07.011_bib39","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/j.1442-2042.2012.03206.x","article-title":"Potential tumor markers of renal cell carcinoma: \u03b1-enolase for postoperative follow up, and galectin-1 and galectin-3 for primary detection","volume":"20","author":"Kaneko","year":"2013","journal-title":"Int J Urol"},{"key":"10.1016\/j.urolonc.2013.07.011_bib40","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1158\/1055-9965.EPI-12-1156","article-title":"Composite three-marker assay for early detection of kidney cancer","volume":"22","author":"Su Kim","year":"2013","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.urolonc.2013.07.011_bib41","first-page":"7310","article-title":"Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma","volume":"48","author":"Elson","year":"1988","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2013.07.011_bib42","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1016\/j.juro.2008.01.101","article-title":"Preoperative nomogram predicting 12-year probability of metastatic renal cancer","volume":"179","author":"Raj","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2013.07.011_bib43","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1464-410X.2007.07170.x","article-title":"Patients with distant metastases from renal cell carcinoma can be accurately identified: external validation of a new nomogram","volume":"101","author":"Hutterer","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2013.07.011_bib44","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.eururo.2011.06.041","article-title":"Prognostic factors and predictive models in renal cell carcinoma: a contemporary review","volume":"60","author":"Sun","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2013.07.011_bib45","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1093\/jnci\/94.20.1569","article-title":"VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma","volume":"94","author":"Yao","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.urolonc.2013.07.011_bib46","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/path.1034","article-title":"VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma","volume":"196","author":"Schraml","year":"2002","journal-title":"J Pathol"},{"key":"10.1016\/j.urolonc.2013.07.011_bib47","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/j.eururo.2006.05.043","article-title":"Hypoxia-inducible factor 1alpha expression in renal cell carcinoma analyzed by tissue microarray","volume":"50","author":"Lidgren","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2013.07.011_bib48","doi-asserted-by":"crossref","first-page":"7388","DOI":"10.1158\/1078-0432.CCR-07-0411","article-title":"Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma","volume":"13","author":"Klatte","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2013.07.011_bib49","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1464-410X.2004.04605.x","article-title":"Expression of vascular endothelial growth factor protein in human renal cell carcinoma","volume":"93","author":"Jacobsen","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2013.07.011_bib50","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.humpath.2007.02.014","article-title":"Plasma level and tissue expression of vascular endothelial growth factor in renal cell carcinoma: a prospective study of 50 cases","volume":"38","author":"Rioux-Leclercq","year":"2007","journal-title":"Hum Pathol"},{"key":"10.1016\/j.urolonc.2013.07.011_bib51","doi-asserted-by":"crossref","first-page":"4757","DOI":"10.1200\/JCO.2007.12.1087","article-title":"Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma","volume":"25","author":"Leibovich","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2013.07.011_bib52","first-page":"2953","article-title":"Soluble carbonic anhydrase IX is not an independent prognostic factor in human renal cell carcinoma","volume":"30","author":"Papworth","year":"2010","journal-title":"Anticancer Res"},{"key":"10.1016\/j.urolonc.2013.07.011_bib53","doi-asserted-by":"crossref","first-page":"e35661","DOI":"10.1371\/journal.pone.0035661","article-title":"Identification of a 4-microRNA signature for clear cell renal cell carcinoma metastasis and prognosis","volume":"7","author":"Wu","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.urolonc.2013.07.011_bib54","first-page":"345","article-title":"C-reactive protein and the acute phase response","volume":"27","author":"Gewurz","year":"1982","journal-title":"Adv Intern Med"},{"key":"10.1016\/j.urolonc.2013.07.011_bib55","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/BF03256414","article-title":"Preoperative C-reactive protein level adjusted for comorbidities and lifestyle factors predicts overall mortality in localized renal cell carcinoma","volume":"15","author":"Michigan","year":"2011","journal-title":"Mol Diagn Ther"},{"key":"10.1016\/j.urolonc.2013.07.011_bib56","first-page":"524981","article-title":"Preoperative erythrocyte sedimentation rate independently predicts overall survival in localized renal cell carcinoma following radical nephrectomy","volume":"2012","author":"Cross","year":"2012","journal-title":"Int J Surg Oncol"},{"key":"10.1016\/j.urolonc.2013.07.011_bib57","doi-asserted-by":"crossref","first-page":"E348","DOI":"10.1111\/bju.12067","article-title":"Validation of serum C-reactive protein (CRP) as an independent prognostic factor for disease-free survival in patients with localised renal cell carcinoma (RCC)","volume":"111","author":"De Martino","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2013.07.011_bib58","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/bjc.2012.565","article-title":"Erythrocyte sedimentation rate and anaemia are independent predictors of survival in patients with clear cell renal cell carcinoma","volume":"108","author":"Choi","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urolonc.2013.07.011_bib59","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity\u2019s roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.urolonc.2013.07.011_bib60","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.semcancer.2007.06.004","article-title":"Immune suppression in renal cell carcinoma","volume":"17","author":"Frankenberger","year":"2007","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.urolonc.2013.07.011_bib61","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.coi.2011.12.009","article-title":"Targeting the PD-1\/B7-H1(PD-L1) pathway to activate anti-tumor immunity","volume":"24","author":"Topalian","year":"2012","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.urolonc.2013.07.011_bib62","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2013.07.011_bib63","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2013.07.011_bib64","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1158\/0008-5472.CAN-05-4303","article-title":"Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up","volume":"66","author":"Thompson","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2013.07.011_bib65","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/cncr.22840","article-title":"Ki-67 and coagulative tumor necrosis are independent predictors of poor outcome for patients with clear cell renal cell carcinoma and not surrogates for each other","volume":"110","author":"Tollefson","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2013.07.011_bib66","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ijrobp.2013.01.016","article-title":"Ki-67 is an independent predictor of metastasis and cause-specific mortality for prostate cancer patients treated on radiation therapy oncology group (RTOG) 94-08","volume":"86","author":"Verhoven","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.urolonc.2013.07.011_bib67","doi-asserted-by":"crossref","DOI":"10.1007\/s12282-012-0337-2","article-title":"Ki-67 evaluation at the hottest spot predicts clinical outcome of patients with hormone receptor-positive\/HER2-negative breast cancer treated with adjuvant tamoxifen monotherapy","author":"Honma","year":"2013","journal-title":"Breast Cancer"},{"key":"10.1016\/j.urolonc.2013.07.011_bib68","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/sj.cdd.4400691","article-title":"Novel survivin-related members of the inhibitor of apoptosis (IAP) family","volume":"7","author":"Wenzel","year":"2000","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.urolonc.2013.07.011_bib69","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/ijc.10450","article-title":"Distinct in vivo expression patterns of survivin splice variants in renal cell carcinomas","volume":"100","author":"Mahotka","year":"2002","journal-title":"Int J Cancer"},{"key":"10.1016\/j.urolonc.2013.07.011_bib70","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.urology.2006.09.024","article-title":"Expression of survivin in renal cell carcinomas: association with pathologic features and clinical outcome","volume":"69","author":"Byun","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2013.07.011_bib71","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.urolonc.2009.09.001","article-title":"Significance of P-glycoprotein, p53, and survivin expression in renal cell carcinoma","volume":"29","author":"Baytekin","year":"2011","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2013.07.011_bib72","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/cncr.21952","article-title":"High expression levels of survivin protein independently predict a poor outcome for patients who undergo surgery for clear cell renal cell carcinoma","volume":"107","author":"Parker","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2013.07.011_bib73","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/j.biocel.2005.05.004","article-title":"Roles of fascin in human carcinoma motility and signaling: prospects for a novel biomarker?","volume":"37","author":"Hashimoto","year":"2005","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.urolonc.2013.07.011_bib74","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00345-006-0110-2","article-title":"Association of EMMPRIN and fascin expression in renal cell carcinoma: correlation with clinicopathological parameters","volume":"25","author":"Tsai","year":"2007","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2013.07.011_bib75","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.urology.2006.03.032","article-title":"Biologic significance of fascin expression in clear cell renal cell carcinoma: systematic analysis of primary and metastatic tumor tissues using a tissue microarray technique","volume":"68","author":"Zigeuner","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2013.07.011_bib76","first-page":"1287","article-title":"Increasing expression of fascin in renal cell carcinoma associated with clinicopathological parameters of aggressiveness","volume":"21","author":"Jin","year":"2006","journal-title":"Histol Histopathol"},{"key":"10.1016\/j.urolonc.2013.07.011_bib77","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/nrm1261","article-title":"Met, metastasis, motility and more","volume":"4","author":"Birchmeier","year":"2003","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.urolonc.2013.07.011_bib78","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/ng0597-68","article-title":"Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas","volume":"16","author":"Schmidt","year":"1997","journal-title":"Nat Genet"},{"key":"10.1016\/j.urolonc.2013.07.011_bib79","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1586\/era.09.43","article-title":"Targeting the Met signaling pathway in renal cancer","volume":"9","author":"Giubellino","year":"2009","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.urolonc.2013.07.011_bib80","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1093\/annonc\/mds463","article-title":"c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma","volume":"24","author":"Gibney","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2013.07.011_bib81","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1128\/MCB.19.2.1262","article-title":"A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development","volume":"19","author":"Nielsen","year":"1999","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.urolonc.2013.07.011_bib82","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0378-1119(01)00866-6","article-title":"The involvement of a conserved family of RNA binding proteins in embryonic development and carcinogenesis","volume":"287","author":"Yaniv","year":"2002","journal-title":"Gene"},{"key":"10.1016\/j.urolonc.2013.07.011_bib83","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S1470-2045(06)70732-X","article-title":"Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study","volume":"7","author":"Jiang","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2013.07.011_bib84","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1002\/cncr.23296","article-title":"External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma","volume":"112","author":"Hoffmann","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2013.07.011_bib85","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1002\/cncr.24263","article-title":"Development and evaluation of BioScore: a biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma","volume":"115","author":"Parker","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2013.07.011_bib86","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2013.07.011_bib87","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2008.19.5511","article-title":"Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial","volume":"27","author":"Escudier","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2013.07.011_bib88","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2013.07.011_bib89","doi-asserted-by":"crossref","first-page":"3958","DOI":"10.1200\/JCO.2006.10.5916","article-title":"Phase I\/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma","volume":"25","author":"Motzer","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2013.07.011_bib90","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1002\/cncr.24280","article-title":"A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer","volume":"115","author":"Amato","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2013.07.011_bib91","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1016\/j.ejca.2011.02.017","article-title":"A phase I study of sirolimus and bevacizumab in patients with advanced malignancies","volume":"47","author":"Cohen","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.urolonc.2013.07.011_bib92","doi-asserted-by":"crossref","first-page":"997","DOI":"10.6004\/jnccn.2011.0084","article-title":"Selecting targeted therapies for patients with renal cell carcinoma","volume":"9","author":"Plimack","year":"2011","journal-title":"J Natl Compr Canc Netw"},{"issue":"Suppl. 7","key":"10.1016\/j.urolonc.2013.07.011_bib93","doi-asserted-by":"crossref","first-page":"vii65","DOI":"10.1093\/annonc\/mds227","article-title":"Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"23","author":"Escudier","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2013.07.011_bib94","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nrclinonc.2009.63","article-title":"Biomarkers of response and resistance to antiangiogenic therapy","volume":"6","author":"Jain","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.urolonc.2013.07.011_bib95","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1158\/0008-5472.CAN-09-3965","article-title":"Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma","volume":"70","author":"Huang","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2013.07.011_bib96","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S1470-2045(12)70241-3","article-title":"Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials","volume":"13","author":"Tran","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2013.07.011_bib97","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1093\/annonc\/mdr047","article-title":"A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma","volume":"23","author":"Zurita","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2013.07.011_bib98","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1200\/JCO.2008.21.7679","article-title":"Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity","volume":"27","author":"Van Erp","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2013.07.011_bib99","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/S1470-2045(11)70266-2","article-title":"Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study","volume":"12","author":"Garcia-Donas","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2013.07.011_bib100","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/sj.bjc.6604456","article-title":"Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer","volume":"99","author":"Van der Veldt","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urolonc.2013.07.011_bib101","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/gm174","article-title":"Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets","volume":"2","author":"Swanton","year":"2010","journal-title":"Genome Med"},{"key":"10.1016\/j.urolonc.2013.07.011_bib102","first-page":"293","article-title":"Tissue-based molecular markers for renal cell carcinoma","volume":"63","author":"Rink","year":"2011","journal-title":"Minerva Urol Nefrol"},{"key":"10.1016\/j.urolonc.2013.07.011_bib103","article-title":"Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: Analysis from the treatment approaches in renal cancer global evaluation trial (TARGET)\u2606","author":"Choueiri","year":"2012","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2013.07.011_bib104","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000342099","article-title":"Changes in circulating pro-angiogenic cytokines, other than VEGF, before progression to sunitinib therapy in advanced renal cell carcinoma patients","volume":"84","author":"Porta","year":"2013","journal-title":"Oncology"},{"key":"10.1016\/j.urolonc.2013.07.011_bib105","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/S1470-2045(12)70231-0","article-title":"VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials","volume":"13","author":"Lambrechts","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2013.07.011_bib106","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1200\/JCO.2011.40.9631","article-title":"Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin","volume":"30","author":"Armstrong","year":"2012","journal-title":"J Clin Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143913003025?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143913003025?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:01:23Z","timestamp":1761040883000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143913003025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":106,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["S1078143913003025"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2013.07.011","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biomarkers of renal cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2013.07.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}